Talphera Inc Stock Price, News & Analysis

Talphera (Nasdaq: TLPH) will release third quarter 2025 financial results after market close on Wednesday, November 12, 2025.

The company will host a live webcast and conference call on Nov 12, 2025 at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a corporate update. The webcast includes a slide presentation and a replay that will be available on the Talphera investor website for 90 days after the event.

Investors can join the conference call via 1-800-836-8184 (North America) or 1-646-357-8785 (international); conference ID 08207. Webcast links are posted in Investors > News & Events > Upcoming Events at www.talphera.com.

Talphera (Nasdaq: TLPH) appointed Joe Todisco, CEO of CorMedix (Nasdaq: CRMD), to its Board of Directors effective Oct 21, 2025.

CorMedix made a strategic investment in Talphera in Sept 2025 and, under that transaction, gained the right to nominate a board representative and a 60-day exclusive negotiation period triggered by the announcement of primary endpoint and topline results from the NEPHRO CRRT clinical study. Talphera and CorMedix cite potential regulatory progress for Niyad with management referencing a possible approval in 2026.

Talphera (NASDAQ:TLPH) has secured a private placement financing of up to $29 million led by CorMedix Inc. as the strategic investor, along with institutional investors including Nantahala Capital, Rosalind Advisors, and Rock Springs Capital. The financing includes $17 million in the first closing (expected September 10, 2025) and potential $12 million in a second tranche upon achieving the primary endpoint in the NEPHRO CRRT study.

The first closing involves issuing 25,036,363 shares at $0.55 per share and 5,845,455 pre-funded warrants at $0.549. CorMedix receives a 60-day exclusivity period to negotiate Talphera's acquisition following NEPHRO study results and gains board nomination rights. The funding is expected to support Talphera through the planned Niyad PMA approval in H2 2026.

Talphera (NASDAQ:TLPH) has reached a significant milestone in its pivotal NEPHRO CRRT clinical trial, enrolling 17 patients, representing approximately 25% of the targeted 70-patient enrollment. This achievement fulfills a requirement for the second tranche of their March 2025 three-tranche financing agreement.

The company reports an accelerated recruitment rate from new profile clinical sites, with over 90% of enrolled patients coming from these new locations. With six additional sites expected to begin enrollment in Q3, Talphera remains confident in completing the study by the end of 2025.

Talphera (Nasdaq: TLPH) reported Q2 2025 financial results and provided updates on its NEPHRO clinical study. The company has enrolled 15 patients in the registrational study, which remains on track for completion by year-end. Cash position stood at $6.8 million as of June 30, 2025.

Key financial metrics include a net loss of $3.5 million ($0.10 per share) in Q2 2025, improved from $3.8 million loss in Q2 2024. Operating expenses decreased to $3.7 million from $4.3 million year-over-year. The company secured a three-tranche financing of up to $14.8 million, with the first tranche of $4.9 million closed in April 2025.

Talphera revised its 2025 cash operating expense guidance to $16-17 million, down from the previous $17-19 million range.

Talphera (Nasdaq: TLPH), a specialty pharmaceutical company, will release its Q2 2025 financial results on Thursday, August 14, 2025 after market close. The company will host a conference call and webcast at 4:30 PM ET/1:30 PM PT to discuss the results and provide a business update.

Investors can access the webcast through Talphera's website investor section, which will include a slide presentation. A replay will be available for 90 days. For those joining by phone, North American callers can dial 1-800-836-8184, while international callers should use 1-646-357-8785 with conference ID 32530.

[]

Talphera (NASDAQ: TLPH) reported its Q1 2025 financial results and provided corporate updates. The company's cash position stands at $9.8 million after including proceeds from April's private placement financing. Key highlights include: FDA approval to reduce NEPHRO CRRT clinical study patients from 166 to 70, with 90% power for the primary endpoint. The company secured up to $14.8 million in financing led by existing investors, with the first tranche of $4.4 million closed in April 2025. Q1 2025 financial results showed a net loss of $2.7 million ($0.10 per share), improved from $4.0 million loss in Q1 2024. Operating expenses decreased to $2.9 million from $4.2 million year-over-year. The company activated three new clinical study sites in 2025 and expects five more by mid-year, targeting study completion by year-end.

Talphera (NASDAQ: TLPH), a specialty pharmaceutical company specializing in innovative therapies for medically supervised settings, has scheduled its first quarter 2025 financial results announcement and corporate update for Wednesday, May 14, 2025. The company will release its financial results after market close, followed by a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time.

Investors can access the webcast through Talphera's website or join the conference call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (international) using conference ID 58894. A replay of the webcast will be available on the company's website for 90 days following the event.

Talphera (NASDAQ: TLPH) announced key developments in its Q4 and full year 2024 financial results. The FDA approved reducing the NEPHRO CRRT study patient count from 166 to 70, maintaining 90% power for the primary endpoint. The company secured potential financing of up to $14.8 million through private placement.

Financial highlights include $8.9 million in cash and cash equivalents as of December 31, 2024. Q4 2024 saw reduced operating expenses with combined R&D and SG&A of $3.0 million, down from $4.6 million in Q4 2023. Net loss improved to $1.9 million ($0.07 per share) compared to $4.5 million ($0.25 per share) in Q4 2023.

The company projects 2025 cash operating expenses between $18-19 million, covering the NEPHRO CRRT registration trial completion expected by year-end 2025.